ArticleJournal of molecular medicine (Berlin, Germany)2025
Unproductive alternative splicing of ATM exon 7: mapping of critical regulatory elements and identification of 34 spliceogenic variants.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Experimental Mis-Splicing Assessment and ACMG/AMP-Guided Classification of 47International journal of molecular sciences · 2026Article
- Prognostic Significance of DNA Repair Gene mRNA Expression in Early-Stage Breast Cancer: Insights into Clinical Relevance.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
ATM loss-of-function variants are significantly associated with increased breast cancer risk. ATM exon 7 skipping (△(E7)) is a naturally-occurring alternative splicing event, which introduces a premature termination codon and represents a form of gene-expression regulation via unproductive splicing. Disruption of splicing regulatory elements (SRE) by variants can lead to mis-splicing, potentially contributing to disease susceptibility. To study the regulatory mechanisms of △(E7) and the impact of exonic variants on splicing, a combined in silico/minigene approach was employed, using the construct mgATM_4-9 (exons 4-9) that recapitulates this splicing event. HEXplorer analysis of ATM exon 7 predicted two splicing enhancer-rich regions (c.665-681 and c.867-898). Deletions of these intervals in mgATM_4-9 significantly increased △(E7) (57-96%), revealing their critical role for exon 7 inclusion. Forty-eight candidate variants (HEXplorer, △HZEI score < -40) within these SRE-rich segments were functionally assayed, 34 of which (71%) impaired exon 7 recognition. Nineteen variants presented strong impacts with high expression of △(E7)-transcripts (69-96%), of which c.668A > T, c.680C > A and c.680C > T exhibited particularly strong effects (4-13% full-length transcripts). DeepCLIP analysis suggested that SR proteins SRSF7 and SRSF10 play a positive regulatory role in exon 7 inclusion. Eight variants were classified as likely pathogenic according to ACMG/AMP-based guidelines. Furthermore, nine missense and two synonymous variants with strong impacts (16-29% full-length transcripts) might represent intermediate risk alleles. This work collectively demonstrates the intricate nature of ATM exon 7 recognition, regulated by cis-acting SREs, emphasizing the value of in silico predictions for initial variant filtering and minigene assays for dissecting splicing regulation and clinical interpretation of variants. KEY MESSAGES: Frameshift ATM exon 7 skipping is an unproductive alternative splicing event that may represent a form of gene-expression regulation. Two SRE-rich intervals are involved in exon 7 recognition. Thirty-four out of 48 tested variants located at these intervals disrupted exon 7 inclusion. Nineteen variants showed strong impacts on splicing. All variant types can impair splicing: 23 missense, 7 nonsense, and 4 synonymous variants upregulate exon 7 skipping. Eight variants were classified as likely pathogenic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.